With additional 25 sales representatives for Uceris, PFUDA of Ruconest by 4/16/2014, raised guidance to $355-360M and EPS to $1.21-1.26, decrease R&D expenses, $140M cash, filing four investigational new drug applications, PAR money, moving Uceris into 2 programs in 2014, P2 for SAN-300 for rheumatoid arthritis by the end of this year.
Yes, I agree. But where were you all when I was singlehandedly defending this stock today? Whoever was driving it down obviously has serious cred, since no one was contesting them. Nevertheless, I ended up with 2500 more shares than I started the day with and some small tax deductible trading losses. I say 28 is easy and 30 likely within months.